Market Research Report
Autoimmune Disease Diagnosis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
|Published by||IMARC Services Private Limited||Product code||988274|
|Published||Content info||142 Pages
Delivery time: 2-3 business days
|Autoimmune Disease Diagnosis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026|
|Published: February 2, 2021||Content info: 142 Pages||
The global autoimmune disease diagnosis market reached a value of US$ 4.4 Billion in 2020. An autoimmune disease refers to a condition wherein the immune system attacks and destroys healthy cells, tissues, and organs of the body. In the longer run, it can also lead to abnormal growth of an organ and changes in organ function. Currently, more than 80 different autoimmune disorders have been identified by scientists, out of which Systemic Lupus Erythematosus (SLE), multiple sclerosis, rheumatoid arthritis, and type I diabetes, are the most common. Depending on the disorder, the doctor uses a combination of methods, which include a physical examination, medical history, blood tests, biopsy, and X-rays, to provide an effective diagnosis. They prescribe anti-inflammatory and immunosuppressant drugs, physical therapy, surgery, and injections, to control the overactive immune response and provide relief from symptoms.
Owing to the rising prevalence of autoimmune diseases, healthcare professionals around the world are focusing on the adoption of advanced technologies to conduct multiple tests with faster and more precise results. Apart from this, a large number of research and diagnostics institutes are undertaking public awareness campaigns to educate individuals about autoimmune diseases and their possible treatments and diagnosis, which is positively influencing the market growth. Furthermore, several governing authorities, along with non-governing organizations, are funding various programs to develop novel therapeutics. For instance, the AMP RA/SLE Program, launched by the Accelerating Medicines Partnership (AMP), is a public-private partnership between the National Institutes of Health (NIH), the US Food and Drug Administration (FDA) and multiple non-profit organizations. The program aims to identify relevant drug targets for the treatment of autoimmune diseases. Looking forward, IMARC Group expects the global autoimmune disease diagnosis market to grow at a CAGR of 8.10% during 2021-2026.